GRAIL, Inc. (NASDAQ:GRAL) Given Consensus Recommendation of “Hold” by Brokerages

Shares of GRAIL, Inc. (NASDAQ:GRAL) have been assigned a consensus recommendation of “Hold” from the ten ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have issued a buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $67.7778.

A number of research analysts have weighed in on the stock. Wolfe Research assumed coverage on shares of GRAIL in a research report on Tuesday, June 2nd. They set a “peer perform” rating on the stock. The Goldman Sachs Group assumed coverage on shares of GRAIL in a report on Friday, June 5th. They issued a “neutral” rating and a $60.00 target price for the company. Wall Street Zen raised shares of GRAIL from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. TD Cowen reissued a “buy” rating on shares of GRAIL in a research report on Wednesday, July 15th. Finally, Piper Sandler raised their price objective on shares of GRAIL from $54.00 to $56.00 and gave the stock a “neutral” rating in a research note on Wednesday, May 6th.

Insider Buying and Selling at GRAIL

In other news, insider Andrew John Partridge sold 1,491 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $61.08, for a total value of $91,070.28. Following the sale, the insider directly owned 163,738 shares in the company, valued at approximately $10,001,117.04. This represents a 0.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 1.83% of the company’s stock.

Hedge Funds Weigh In On GRAIL

A number of hedge funds have recently added to or reduced their stakes in GRAL. Fifth Third Bancorp raised its position in GRAIL by 15,733.3% during the 1st quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock valued at $25,000 after purchasing an additional 472 shares in the last quarter. N.E.W. Advisory Services LLC bought a new position in GRAIL during the 4th quarter worth about $26,000. Comerica Bank grew its holdings in GRAIL by 59.2% during the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after acquiring an additional 173 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in GRAIL during the 4th quarter valued at about $28,000. Finally, Geneos Wealth Management Inc. increased its position in GRAIL by 160.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 585 shares of the company’s stock valued at $30,000 after purchasing an additional 360 shares during the period.

GRAIL Trading Down 0.4%

GRAL opened at $70.36 on Friday. The stock has a 50-day moving average of $66.38 and a 200 day moving average of $68.77. GRAIL has a 12 month low of $29.95 and a 12 month high of $118.84. The firm has a market cap of $3.02 billion, a P/E ratio of -6.78 and a beta of 3.22.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($2.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.76) by $0.47. GRAIL had a negative return on equity of 16.42% and a negative net margin of 253.22%.The business had revenue of $40.78 million for the quarter, compared to the consensus estimate of $39.16 million. On average, research analysts forecast that GRAIL will post -10.91 earnings per share for the current fiscal year.

Trending Headlines about GRAIL

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: No new positive company-specific developments were reported in the last 24-36 hours.
• Neutral Sentiment: Multiple firms, including Rosen Law Firm, Pomerantz, Schall, Berger Montague, and others, reminded investors that a securities class action has been filed and that the August 4, 2026 lead-plaintiff deadline is approaching. Article Title
• Neutral Sentiment: Legal notices said the lawsuit covers investors who purchased GRAIL stock between May 13, 2025 and February 19, 2026, with several firms encouraging affected shareholders to seek lead-plaintiff status or contact counsel. Article Title
• Negative Sentiment: The repeated class-action reminders may weigh on sentiment because they reinforce concerns about potential liability, legal costs, and reputational damage for GRAIL if the allegations gain traction. Article Title

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.